Published on 23/12/2025
Specialty CROs Supporting Rare Disease Clinical Trials: Top Examples
Rare diseases—often defined as conditions affecting fewer than 200,000 people in the US—present unique challenges for clinical trials. These include small patient populations, geographic dispersion, lack of historical data, and complex regulatory pathways. To address these hurdles, many sponsors turn to niche Contract Research Organizations (CROs) that specialize in rare disease research. These CROs bring therapeutic focus, operational creativity, and deep engagement with advocacy groups. In this tutorial, we explore leading examples of niche CROs that focus on rare disease clinical trials, and how they partner with sponsors to accelerate orphan drug development.
1. Why Rare Diseases Need Specialized CROs:
Unlike high-prevalence indications, rare disease studies demand CROs that can:
- Find and recruit hard-to-reach patients
- Design custom endpoints and outcome measures
- Work closely with regulators for accelerated pathways
- Engage caregivers and advocacy groups effectively
Generalist CROs may lack the infrastructure or networks to manage these requirements. That’s where niche CROs come in.
2. Premier Niche CROs in Rare Disease Research:
Medpace
- Focus: Rare metabolic, cardiovascular, and pediatric diseases
- Strengths: In-house medical experts, global site relationships, regulatory consulting
- Notable: Integrated model with labs, imaging, and pharmacovigilance under one roof
PRA Health Sciences (now part of ICON)
- Focus: Rare
PSI CRO
- Focus: Hematologic, rare oncology, and rare CNS conditions
- Strengths: Site activation speed and low screen failure rates
- Notable: Proven delivery of complex Phase II/III trials in rare diseases
Raremark (now part of Informa)
- Focus: Rare disease patient engagement and community building
- Strengths: Recruitment via trusted patient communities
- Notable: Integration with patient registries and natural history data collection
Orphanos Clinical Trials
- Focus: Ultra-rare and pediatric indications
- Strengths: End-to-end clinical operations with bespoke support
- Notable: Custom protocol design and global rare site partnerships
3. Case Study: Gene Therapy for SMA (Spinal Muscular Atrophy)
A mid-size biotech needed a CRO to support a Phase II gene therapy study in Spinal Muscular Atrophy. Their chosen CRO—an experienced rare neuromuscular disease specialist—delivered:
- Patient referrals through advocacy groups and social media
- Engagement with expert KOLs to refine the primary endpoint
- Regulatory guidance aligned with EMA fast-track protocol standards
- Real-time reporting through integrated dashboards
The result was a 95% enrollment rate and regulatory acceptance of the novel trial design—accelerating market access by nearly a year.
4. Benefits of Working with Niche Rare Disease CROs:
- Scientific Depth: Domain experts that advise on protocol design and biomarkers
- Faster Recruitment: Direct access to rare disease patient networks
- Regulatory Insight: Familiarity with orphan drug pathways, such as RMAT or PRIME
- Operational Flexibility: Willingness to customize systems and workflows
5. Operational Tactics Used by Rare Disease CROs:
- Remote consent and data capture to reduce travel burden
- Real-world data (RWD) use for historical controls
- Engagement of family caregivers in trial operations
- Close collaboration with academic medical centers
6. Role in Orphan Drug Designation and FDA Interactions:
Many niche CROs actively support sponsors through the Orphan Drug Designation (ODD) process, helping with:
- Pre-IND meeting preparations
- Stability testing summaries aligned with Stability Studies requirements
- Fast Track and Breakthrough Therapy Designation applications
- CMC module input and justification for small-batch production
These partnerships are especially critical for first-in-human studies or trials with one-time gene therapies.
7. Challenges in Rare Disease CRO Engagement:
Despite their strengths, niche CROs may come with certain trade-offs:
- Limited global presence or scalability for large Phase III programs
- Need for close collaboration and sponsor-side oversight
- Higher per-patient cost due to intensive support needs
However, the quality and regulatory readiness they bring often outweigh these limitations.
8. Selection Criteria for Sponsors:
When selecting a niche CRO for rare diseases, sponsors should assess:
- Track record in the specific indication or class (e.g., neurometabolic, immunologic)
- Regulatory experience with Pharma GMP documentation and ODD filings
- Established site and patient relationships
- Operational tools for remote, decentralized support
Conclusion: Specialized Partnerships for Specialized Needs
Rare diseases demand rare partnerships. Niche CROs provide the therapeutic intelligence, patient access, and regulatory finesse required to bring breakthrough treatments to underserved populations. Sponsors should view these organizations not as vendors but as extensions of their development teams—trusted collaborators who understand the nuance and urgency of rare disease research. As more sponsors focus on precision medicine and gene therapies, niche CROs will remain essential to trial success and patient impact.